GO
Loading...

Enter multiple symbols separated by commas

Stocks Johnson & Johnson

More

  • SALT LAKE CITY— A legal battle over a hotly contested Utah law banning minimum prices for contact lenses is set to come before a federal appeals court on Thursday. Alcon Laboratories, Johnson& Johnson and Bausch& Lomb call the law a brazen overreach written specifically to help Utah- based discount seller 1-800 Contacts. The manufacturers are appealing a ruling...

  • British ingredients firm Tate& Lyle makes sucralose and sells it to J&J, which in turn markets it worldwide under the Splenda brand in familiar yellow packages used in homes and in restaurants. Tate& Lyle also makes sucralose used in beverages and other retail products, unrelated to the company's long-standing relationship with J&J and Splenda.

  • Aug 25- Privately held Heartland Food Products Group said on Tuesday it would buy Johnson& Johnson's low-calorie artificial sweetener, Splenda. J&J's unit McNeil Nutritionals developed Splenda, an artificial sweetener made from sucralose, jointly with British ingredients firm Tate& Lyle. Tate& Lyle supplies the sucralose and markets the sweetener in Europe.

  • The new executive, Lynn Pendergrass, previously held senior positions at Johnson& Johnson, Hewlett-Packard Co and General Electric Co, Sears said in a statement on Monday. Given her background promoting big global brands, the Pendergrass appointment could signal that Sears wants to look at expanding sales of Kenmore, Diehard and Craftsman products outside...

  • Pisani: Stocks' dramatic slide hits ETFs Monday, 24 Aug 2015 | 7:26 PM ET
    Trader on the floor of the New York Stock Exchange.

    There was, for lack of a better word, "pricing havoc" in some ETFs.

  • Blue chips to buy on Dow's drubbing Friday, 21 Aug 2015 | 6:43 PM ET
    China's first Disney flagship store in Shanghai last May.

    After the Dow Jones industrial average plummeted 530 points Friday, CNBC "Fast Money" traders looked for value.

  • Stocks plunge 2% on Fed, growth concerns Thursday, 20 Aug 2015 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed near session lows as investors weighed continued uncertainty about the timing of a rate hike and concerns about global growth.

  • Aug 20- A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday. Besides burnishing the image of the year-old drug, Jardiance, the results could raise the...

  • Correction: Disney Startups story Tuesday, 18 Aug 2015 | 3:56 PM ET

    GLENDALE, Calif.— In some versions of an Aug. 11 story about Disney's accelerator program, Techstars was incorrectly spelled with a capital' S' in the middle.. GLENDALE, Calif.— If it weren't for someone willing to entertain a new idea, the new "Star Wars" droid, BB-8, wouldn't be rolling into living rooms this holiday season. But in July 2014, the CEO of Lucasfilm-parent...

  • NEW YORK, Aug 18- In July 2013, California urogynecologist Andrew Cassidenti received an email from an entrepreneur named Otto Fisher, who had a proposition. In a phone call, Fisher said he needed doctors to operate at outpatient centers in California and Las Vegas. Fisher said he could guarantee Cassidenti $2,500 for every surgery the doctor performed, "whether...

  • Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Dublin- based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of blood cancer. Mallinckrodt's purchase of Therakos from...

  • Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Dublin- based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of skin cancer. Mallinckrodt's purchase of Therakos from investment...

  • *Mallinckrodt shares up flat in early trading. Aug 10- Dublin- based drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings. Mallinckrodt's purchase of Therakos from investment firm The Gores Group comes...

  • Mallinckrodt buys immunotherapy maker for $1.33B Monday, 10 Aug 2015 | 8:18 AM ET
    Mallinckrodt Pharmaceuticals offices in St. Louis.

    Mallinckrodt said it would buy immunotherapy company Therakos in a deal valued at about $1.33 billion.

  • NEW YORK, Aug 9- The question investors are pondering during the remainder of the northern hemisphere summer is whether major stock markets can sustain this year's relatively high valuations given the slump in commodity prices, a firm U.S. dollar, and the likelihood of a Federal Reserve interest rate rise in September. The U.S. monthly employment report on...

  • NEW YORK, Aug 7- Johnson& Johnson subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic scalpel that cuts and seals blood vessels. The U.S. Court of Appeals for the Federal Circuit on Friday said on Friday a lower court should not...

  • NEW YORK, Aug 7- Johnson& Johnson subsidiary Ethicon Endo-Surgery Inc will get a second chance to hold rival surgical instrument maker Covidien Plc liable for allegedly infringing two patents on a specialized ultrasonic device that cuts and seals blood vessels. The U.S. Court of Appeals for the Federal Circuit on Friday said a lower court should not have...

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...